Cannabidiol, a non-psychoactive constituent of cannabis, has garnered much attention after United States Food and Drug Administration approved Epidiolex® for oral use. Although therapeutic effect of cannabidiol after systemic absorption has been investigated extensively, its therapeutic potential in treating skin disorders after local delivery still needs further exploration. Our study has investigated the effect of cannabidiol concentration, chemical enhancers, and essential oils on percutaneous absorption of cannabidiol. In vitro permeation tests were conducted on human skin. The 24 h study results suggest no significant difference in amount of drug absorbed into skin, between 5% (242.41 ± 12.17 µg/cm) and 10% (232.79 ± 20.82 cm) cannabidiol solutions. However, 1% delivered (23.02 ± 4.74 µg/cm) significantly lower amount of drug into skin than 5% and 10%. Transcutol and isopropyl myristate did not enhance delivery of cannabidiol. However, oleic acid was found to be useful as chemical enhancer. Oleic acid (43.07 ± 10.11 µg/cm) had significantly higher cannabidiol delivery into skin than the group without oleic acid (10.98 ± 3.40 µg/cm) after a 4 h in vitro permeation study. Essential oils at concentrations tested had lower total cannabidiol delivery when compared to control. This study's findings will help guide future research on the pharmacological effect of percutaneously delivered cannabidiol on inflammatory skin disorders.

Annuellement, plus de 19 millions d’individus consomment de la cocaïne dans le monde et sur ce nombre, 16 % développeront un trouble de l’usage de cocaïne (TUC). Ce trouble est associé à de hauts niveaux de problèmes de santé physique, mentale ainsi que sociale et aucun traitement pharmacologique efficace n’est actuellement disponible. Le cannabidiol (CBD) a suscité un important intérêt en tant que traitement prometteur pour les troubles d’usage de substance (TUS). Par exemple, certaines données probantes suggèrent que le CBD pourrait diminuer la consommation de cocaïne et possèderait des propriétés anxiolytiques. De plus, le CBD augmenterait les taux plasmatiques d'anandamide (AEA), influençant possiblement certaines de ses propriétés thérapeutiques. L’objectif général de cette thèse était d’évaluer l’efficacité du CBD par rapport au placebo pour le traitement du TUC. Plus précisément, dans le premier article présenté dans cet ouvrage, nous nous sommes principalement intéressés à l’effet du CBD sur l’envie impérieuse de consommer (craving), sur la consommation de cocaïne et sur le délai avant une rechute, et ce chez des participants avec un TUC. Par la suite, dans le second article, nous avons étudié les possibles propriétés anxiolytiques du CBD chez nos participants. Finalement, dans le troisième article de cette thèse, il a été question de l’effet du CBD sur les taux plasmatiques d’AEA. Un essai randomisé contrôlé de supériorité en double insu a été conduit au Centre hospitalier de l’Université de Montréal pour répondre à ces objectifs. L’étude était divisée en deux phases, soit une première où les participants étaient hospitalisés pendant une période de dix jours et une seconde d’une durée de 12 semaines pour effectuer un suivi ambulatoire. Au total, 78 individus (14 femmes) présentant un TUC ont été assignés au hasard, par blocs stratifiés, à 800 mg par jour de CBD (n=40) ou à un placebo (n=38). Les variables primaires de cette étude étaient le craving induit par un scénario de consommation de cocaïne (phase I) et le délai avant une rechute (phase II). Concernant les variables secondaires, nous avions le craving induit par un scénario de stress (phase I) et l’utilisation de cocaïne (phase II). Finalement, plusieurs variables exploratoires ont été étudiées telles que l’anxiété, les niveaux d’AEA et de cortisol ainsi que les symptômes de sevrage. Dans un premier lieu, nous avons démontré que le CBD était similaire au placebo pour induire un craving suite à un scénario de consommation de cocaïne ainsi qu’à un scénario de stress. De même, le délai avant une rechute ainsi que la consommation de cocaïne durant la phase II de l’étude étaient similaires entre les deux groupes de traitement. Au niveau des variables exploratoires, les participants des groupes CBD et placebo présentaient des scores d’anxiété ainsi que des niveaux de cortisol et d’AEA similaires. Finalement, le CBD était bien toléré et le principal effet secondaire était la diarrhée. Globalement, nous n’avons trouvé aucune preuve concernant l’efficacité de l’administration quotidienne de 800 mg CBD sur nos différentes variables chez nos participants. Notre étude a mis en évidence l’important besoin de poursuivre la recherche pour identifier un traitement pharmacologique efficace pour aider les individus avec un TUC. / Annually, more than 19 million people use cocaine worldwide. Of that number, 16% will develop cocaine use disorder (CUD). CUD is associated with high levels of physical, mental, as well as social health problems, and no effective pharmacological treatment is currently available. Cannabidiol (CBD) has generated significant interest as a promising treatment for substance use disorders (SUD). For example, some evidence suggests that CBD may decrease cocaine use, and that it may also have anxiolytic properties. In addition, CBD could increase plasma levels of anandamide (AEA), possibly influencing some of its therapeutic properties. The main objective of this thesis was to evaluate the effectiveness of CBD compared to placebo for the treatment of CUD. Specifically, in the first article presented in this thesis, we focused on the effect of CBD on craving, cocaine use, and time to relapse in participants with CUD. Subsequently, in the second article, we investigated the possible anxiolytic properties of CBD in our participants. Finally, in the third article, the effect of CBD on plasma AEA levels was discussed. A randomized, controlled, double-blind superiority trial was conducted at the University of Montreal Hospital Center to explore these objectives. The study was divided into two phases: a first where participants were hospitalized for a period of 10 days, and a second phase consisting of a 12 week outpatient follow-up. A total of 78 individuals (14 women) with CUD were randomly assigned to stratified blocks at 800 mg per day of CBD (n = 40) or placebo (n = 38). The primary outcomes in this study were craving induced by a cocaine use scenario (phase I) and time to relapse (phase II). The secondary outcomes were craving induced by a stress scenario (phase I) and the use of cocaine (phase II). Finally, several exploratory variables were studied such as anxiety, AEA and cortisol levels, as well as withdrawal symptoms. First, we demonstrated that CBD was similar to placebo in inducing craving following a cocaine use scenario as well as a stress scenario. Likewise, the time to relapse, as well as cocaine use during phase II of the study were similar between the two treatment groups. In terms of exploratory outcomes, participants in the CBD and placebo groups had similar anxiety scores, as well as cortisol and AEA levels. Ultimately, CBD was well tolerated and the main adverse event was diarrhea. Overall, we found no evidence regarding the effectiveness of administering daily 800 mg CBD on the various measured outcomes in our participants. Our study highlighted the significant need for further research to identify an effective pharmacological treatment to help individuals with a CUD.

La synaptogenèse est un processus biologique aboutissant à la mise en place d’un réseau de connexions neuronales, par la genèse de synapses. La mise en place de ce réseau de connexions est essentielle au développement du système nerveux central (SNC) et de ses fonctions. Tout comme les autres étapes du développement du SNC, la synaptogenèse est régulée par une multitude de signaux cellulaires, et le système endocannabinoïde en fait partie. Les dérivés du cannabis tel que le Δ-9-tétrahydrocannabinol (THC) et le cannabidiol (CBD) sont capables de traverser la barrière placentaire et de se retrouver dans le lait maternel. Par leur interaction avec le SNC, entre autres, ces phytocannabinoïdes sont capables d’influencer son développement. Le récepteur couplé à une protéine G 55 (GPR55) est catégorisé comme récepteur atypique du système endocannabinoïde, et il est capable d’être antagonisé par le CBD. Il a été prouvé par de précédentes études qu’il est lui aussi impliqué dans le développement du SNC, notamment dans le guidage et la croissance des axones durant les périodes fœtale et périnatale. Dans la littérature, il est souvent rapporté que les signaux impliqués dans le guidage axonal le sont aussi dans la synaptogenèse. C’est pourquoi le présent mémoire vise à examiner le rôle du récepteur GPR55 et l’effet de sa modulation par le CBD dans la formation de contacts synaptiques. Le modèle utilisé pour cette étude est la culture de neurones corticaux issus d’embryons de souris de génotypes gpr55+/+ et gpr55-/-. Pour comprendre le rôle physiologique de GPR55 dans la synaptogenèse nous avons étudié l’effet de la délétion du récepteur GPR55 à deux temps, Day In Vitro (DIV) 9-10 au début de la synaptogenèse, et à DIV14-15 un temps plus avancé. Ensuite pour comprendre comment le CBD est capable d’influencer la formation de contacts synaptiques de manière dépendante ou non de GPR55, les cultures de neurones corticaux de chaque génotype ont été exposées à DIV9 pour 24h à différentes concentrations du CBD (0,3uM ou 0,6uM ou 1uM). Les effets sur la formation de contacts synaptiques ont été étudiés en immunocytochimie, en immunobuvardage et en électrophysiologie de type patch clamp. Les résultats montrent que la délétion de GPR55 entraine à DIV14-15 une augmentation de la densité des contacts synaptiques, mais une réduction de leur aire et de l’expression de la synaptophysine, en affectant l’activité synaptique. L’exposition au CBD 0,6uM et 1uM entrainent de manière dépendante ou partiellement dépendante à GPR55, une augmentation de la densité des contacts synaptiques sans affecter leur aire, l’expression de protéines synaptiques ainsi que l’activité synaptique. La fréquence de décharge des neurones est diminuée de manière dépendante de GPR55 après l’exposition au CBD 1uM. Ces résultats suggèrent que GPR55 pourrait être un signal important pour l’arrêt de la formation de nouvelles synapses et un signal d’induction pour la maturation des synapses existantes. / Synaptogenesis is a biological process that leads to the establishment of a network of neuronal connections through the genesis of synapses. The formation of this network of connections is essential for the development of the central nervous system (CNS) and its functions. Like other stages of CNS development, synaptogenesis is regulated by multiple cellular signals, and the endocannabinoid system is part of it. Cannabis derivatives such as Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) can cross the placental barrier and be present in breast milk. Through their interaction with the endocannabinoid system, among others, these phytocannabinoids can influence CNS development. The G protein-coupled receptor 55 (GPR55) is categorized as an atypical receptor of the endocannabinoid system, and it can be antagonized by CBD. Previous studies have shown that GPR55 is also involved in CNS development, particularly in the guidance and growth of axons during fetal and perinatal periods. It is often reported in the literature that the signals involved in axonal guidance are also involved in synaptogenesis. Therefore, this study investigates the role of the GPR55 receptor and the effect of its modulation by CBD in the formation of synaptic contacts. The model used for this study consists of cortical neuron cultures from mouse embryos gpr55+/+ and gpr55-/- . To understand the physiological role of GPR55 in synaptogenesis, we studied the effect of gpr55 deletion at two-time points: Day In Vitro (DIV) 9- 10 at the beginning of synaptogenesis, and DIV14-15 at a later time point. Then, to understand how CBD can influence the formation of synaptic contacts, whether dependent or independent of GPR55, cortical neuron cultures of each genotype were exposed to different concentrations of CBD (0.3µM or 0.6µM or 1µM) at DIV9 for 24 hours. The effects on the formation of synaptic contacts were studied through immunocytochemistry, western blot, and patch clamp electrophysiology. The results show that gpr55 deletion leads to an increase in synaptic contact density at DIV14-15 but a reduction in their area and synaptophysin expression, by affecting synaptic activity. Exposure to 0.6µM and 1µM CBD results in a GPR55-dependent or partially dependent increase in synaptic contact density without affecting their area, expression of synaptic proteins, and synaptic activity. The firing frequency of neurons is decreased in a GPR55- dependent manner after exposure to 1µM CBD. These results suggest that GPR55 could be an important signal for stopping the formation of new synapses and an induction signal for the maturation of existing synapses.

Ce projet de recherche porte sur l’étude de la régulation des systèmes cannabinoïdes et vanilloïdes chez Caenorhabditis elegans (C. elegans), dans le but d’évaluer les effets antinociceptifs du tétrahydrocannabinol (THC) et du cannabidiol (CBD). C. elegans est un modèle largement utilisé pour étudier la nociception, visant principalement à caractériser les réponses nociceptives induites par le THC et le CBD, ainsi qu’à identifier les mécanismes et les cibles moléculaires impliqués. Les résultats des études sur l’utilisation du cannabis dans le traitement de la douleur chronique chez les mammifères sont controversés. Cette recherche vise à étudier l’effet du CBD et du THC sur la réponse nociceptive chez C. elegans et à approfondir la compréhension des mécanismes pharmacologiques sous-jacents. La méthodologie consiste à quantifier l’effet antinociceptif du CBD et du THC chez C. elegans par la méthode de la thermotaxie. Les nématodes sauvages (N2) étaient exposés à des concentrations croissantes de phytocannabinoïdes pour évaluer la relation concentration-effet. D’autres tests étaient effectués sur des souches mutantes exprimant des récepteurs cannabinoïdes et vanilloïdes afin d’identifier préalablement leurs cibles. Enfin, les analyses protéomiques et bioinformatiques seront effectuées pour identifier les voies de signalisation et les processus biologiques induits par l’interaction entre les phytocannabinoïdes et leurs cibles. Cette étude démontre l’activité antinociceptive du CBD et du THC chez C. elegans avec des effets rémanents pour THC, en ciblant respectivement le vanilloïde pour le CBD et le cannabinoïde pour les systèmes THC. Les analyses protéomiques et bio-informatiques mettent en évidence des différences significatives dans leurs voies de signalisation et leurs processus biologiques. / The objective of this research project was to focus on studying the regulation of cannabinoid and vanilloid systems in Caenorhabditis elegans (C. elegans) to evaluate the anti-nociceptive effects of tetrahydrocannabinol (THC) and cannabidiol (CBD). C. elegans is a widely used model for studying nociception, with the main objective being to characterize nociceptive responses induced by THC and CBD, as well as identify the underlying molecular mechanisms and targets involved. Recent studies on the use of cannabis for the treatment of chronic pain in mammals have shown controversial results. This research aims to investigate the effect of CBD and THC on the nociceptive response in C. elegans and understand the underlying pharmacological mechanisms. The methodology consisted in quantifying the antinociceptive effect of CBD and THC in C. elegans using the thermotaxis method. WT(N2) were exposed to decreasing concentrations of phytocannabinoids to evaluate the dose and effect relationship. Further tests performed on mutant expressing cannabinoid and vanilloid receptors allowed preliminarily identification of their targets. Finally, proteomic and bioinformatics analyses were used to identify the signaling pathways and biological processes induced by these phytocannabinoids. The result of this study confirmed the antinociceptive effect of CBD and THC in C. elegans, with a remanent effect of THC. This effect is mediated by the vanilloid system for CBD and the cannabinoid system for THC, respectively. Also, proteomics and bioinformatics analyses revealed significant differences in signaling pathways and biological processes.

The impacts of exogenous cannabinoids, such as the chemical constituents of Cannabis sativa like cannabidiol (CBD), on brain regions having a modest number of cannabinoid receptors, for example, the ventromedial hypothalamus, are not yet surely knew. A few researches have shown evidence that ventromedial hypothalamus (VMH) neurons play a role in modulating innate fear-induced behavioural reactions in rodents submitted to experimental models of panic attack, for example those based on prey versus wild snake confrontation paradigm. The panic attack-like state was also potentially induced in laboratory animals by N-Methyl-D-aspartate (NMDA), an excitatory amino acid, which stimulates neurons that organize defensive behavioural reactions in the central nervous system. Despite the fact that CB1 receptor-mediated endocannabinoid signaling mechanism underlies the antiaversive effect of exogenous anandamide in medial hypothalamus, there is still a lack of morphological evidence to support the distribution of CB1 receptors in the VMH. Henceforth, this study was designed to explore the specific pattern of distribution of the CB1 receptors in the VMH and, subsequently, the implication of these receptors in the endocannabinoidmodulated defensive behavioural responses followed by fear-induced antinociception evoked by NMDA microinjected in the VMH. A stainless steel guide-cannula was embedded in the rodent\'s brain coordinated towards VMH by means of stareotaxic surgery. Three different doses of cannabidiol (CBD) were microinjected in the VMH. The most effective dose was used after the pretreatment with the CB1 receptor-antagonist AM251, followed by NMDA microinjection in the VMH. The outcomes demonstrated that the defensive behavioural responses evoked in response to intra-VMH administration of NMDA (6 nmol) were decreased by intra-hypothalamic microinjections of CBD at the highest dose (100 nmol).These effects, however, were blocked by the administration of the CB1 receptor-antagonist AM251 (100 pmol) in the VMH. In addition, the fear-induced antinociception elicited by VMH chemical stimulation diminished after the VMH treatment with CBD, an effect reversed by the intra-diencephalic pretreatment with AM251. These findings suggested that CBD causes panicolytic-like effects when administered in the VMH, and that antiaversive effect recruits the CB1 receptor-endocannabinoid signaling mechanism in VMH. / O papel dos canabinoides exógenos nas regiões do cérebro com um número modesto de receptores cannabinoides, por exemplo, o hipotálamo ventromedial, ainda não está plenamente esclarecido. Algumas pesquisas de nosso grupo, não obstante, mostraram o hipotálamo ventromedial (HVM) exerce modulação de reações comportamentais provocadas pelo medo inato em animais submetidos a um modelo de ataques de pânico. Crises de pânico foram induzidas em animais de laboratório por N-metil-D-aspartato (NMDA), um aminoácido excitatório que, ao ser microinjetado em estruturas do sistema encefálico de aversão, estimula reações comportamentais defensivas no sistema nervoso central que mimetizam as respostas defensivas eliciadas por roedores confrontados com serpentes. Apesar do mecanismo de sinalização endocanabinoide mediado pelos receptores CB1 desempenhar um papel na modulação da neurotransmissão excitadora e inibitória no SNC, ainda há escassez de evidências morfológicas que embasem a distribuição dos receptores CB1 no HVM. Por conseguinte, este estudo foi idealizado para explorar a forma específica de distribuição dos receptores CB1 no HVM e, posteriormente, estudar a implicação desses receptores na modulação de respostas comportamentais defensivas, seguidas por antinocicepção induzida pelo medo, moduladas por endocanabinoides e evocadas por microinjetação de NMDA no HVM. Uma cânula-guia feita de aço inoxidável foi implantada no cérebro do roedor, e direcionada para o HVM por meio de cirurgia estareotóxica. Três diferentes doses de cannabidiol (CBD) foram microinjetadas no HVM. A dosagem mais eficaz foi utilizada após o pré-tratamento do hipotálamo medial com um antagonista do receptor CB1, o AM251, seguido da microinjeção NMDA no HVM. Os resultados demonstraram que as respostascomportamentais defensivas evocadas em resposta à administração intra-HVM de NMDA (6 nmol) foram diminuídas por microinjeções intra-hipotalâmicas de CBD na dose mais alta (100 nmol). Estes efeitos, no entanto, foram atenuados pela administração do antagonista do receptor CB1, AM251, na dose de 100 pmol no HVM. Além disso, a antinocicepção induzida pelo medo foi atenuada pela administração intra-diencefálica de CBA, o que foi revertido pelo pré-tratamenot do HVM com AM251. Esses dados sugerem que o CBD causa efeitos panicolíticos, quando administrado no HVM, envolvendo o mecanismo de sinalização do receptor CB1-endocannabinoide.

A esquizofrenia é uma desordem altamente incapacitante que atinge cerca de 1% da população, envolvendo desequilíbrio da neurotransmissão dopaminérgica e uma hipofunção glutamatérgica. Portadores dessa doença apresentam deficiência do processamento de informações caracterizada por prejuízo no teste de inibição pré-pulso (prepulse inhibition - PPI). Essa condição pode ser reproduzida em modelos experimentais, pelo tratamento com psicoestimulantes, como a anfetamina (ANF) e atenuado/revertido pelo tratamento com antipsicóticos. O canabidiol (CBD) é o principal componente não psicotomimético da Cannabis sativa. Estudos clínicos e pré-clínicos sugerem que o CBD apresenta perfil antipsicótico, com baixa indução de efeitos adversos. Contudo, até o momento poucos estudos foram realizados com o objetivo de investigar os mecanismos farmacológicos e/ou moleculares envolvidos nesse perfil. Os prováveis mecanismos envolvidos com as propriedades antipsicóticas do CBD parecem envolver a ativação de receptores TRPV1 e o aumento da sinalização do endocanabinoide anandamida. No presente estudo, demonstramos que os receptores TRPV1 e o aumento da disponibilidade de anandamida parecem participar do perfil antipsicótico do CBD. Nessas investigações, não observamos participação dos receptores 5-HT1A. A microinjeção de CBD no córtex pré-frontal (CPF), estrutura envolvida com a fisiopatologia da esquizofrenia e um provável sítio para ação de antipsicóticos, não atenuou o prejuízo induzido por ANF no PPI. Recentemente, mecanismos epigenéticos, como a metilação do DNA, têm sido associados à fisiopatologia da esquizofrenia. Nesse sentido, avaliamos o envolvimento da metilação do DNA em estruturas envolvidas com a neurobiologia da esquizofrenia regulada por CBD, sobre as respostas comportamentais induzidas por drogas psicotomiméticas. Verificamos que a ANF causa um aumento da metilação global no estriado ventral, efeito bloqueado pelo pré-tratamento com CBD e de forma semelhante com o antipsicótico clozapina (CLZ). Não observamos alterações na metilação global no CPF. O tratamento com MK-801 não alterou a metilação global nas duas estruturas anteriormente citadas. Protocolo experimental semelhante foi utilizado em mais duas abordagens: (i) a expressão do fator neurotrófico do cérebro (BDNF), relacionado com a manutenção, crescimento e diferenciação dos neurônios está aumentada no hipocampo dos animais tratados com a associação CBD e ANF, padrão semelhante foi observado com a associação CLZ e ANF. (ii) a expressão de fosfo-histona acetilada, um marcador que indica alterações na cromatina, intimamente ligada com as alterações da expressão gênica está aumentada no núcleo acumbens e CPF dos animais tratados com a associação CBD e ANF. Os dados aqui apresentados sugerem que os receptores TRPV1 e o endocanabinoide anandamida parecem estar envolvidos com o perfil antipsicótico do CBD. Pela primeira vez foi demonstrado que tanto o pré-tratamento com CBD ou CLZ podem alterar o aumento da metilação global de DNA induzido por ANF. Além disso, a expressão de BDNF no hipocampo e a expressão de fosfo-histona acetilada podem ser outros mecanismos que merecem atenção em relação ao perfil antipsicótico do CBD. / Schizophrenia is a highly disabling disorder that affects about 1% of the population and involves impaired dopaminergic neurotransmission and glutamatergic hypofunction. Patients with this disorder have a deficiency in information processing characterized by disruption in the prepulse inhibition (PPI) test. This condition can be reproduced in experimental models by treatment with psychostimulants such as amphetamine and attenuated / reversed by treatment with antipsychotics. Cannabidiol (CBD) is the main non-psychotomimetic component of Cannabis sativa. Clinical and preclinical studies suggest that CBD has an antipsychotic profile, with low induction of adverse effects. However, to date, few studies have been carried out to investigate the pharmacological and / or molecular mechanisms involved in this outcome. The likely mechanisms involved with the antipsychotic properties of CBD appear to involve activation of TRPV1 receptors and increased endocannabinoid anandamide signaling. In the present study, we demonstrated that TRPV1 receptors and the increased availability of anandamide appear to participate in the CBD antipsychotic profile. In these investigations, we did not observe participation of 5-HT1A receptors. Microinjection of CBD in the prefrontal cortex, structure involved in the pathophysiology of schizophrenia and a probable site of antipsychotic action, did not attenuate the amphetamine-induced disruption in PPI. Recently, epigenetic mechanisms, such as DNA methylation, have been associated with the pathophysiology of schizophrenia. In this sense, we also evaluated the involvement of DNA methylation in structures involved with the neurobiology of CBD-regulated schizophrenia on behavioral responses induced by psychotomimetic drugs. We found that amphetamine causes increased global methylation in the ventral striatum, an effect blocked by pre-treatment with CBD and similarly with the antipsychotic clozapine. We did not observe changes in the global methylation in prefrontal cortex. Treatment with MK-801 did not alter the global methylation in the two aforementioned structures. Similar experimental protocol was used in two other approaches: (i) brain neurotrophic factor (BDNF) expression, related to the maintenance, growth and differentiation of neurons is increased in the hippocampus of animals treated with CBD and amphetamine; a similar pattern was observed with the association clozapine and amphetamine. (ii) the expression of acetylated phospho-histone, a marker indicating changes in chromatin, closely linked to changes in gene expression is increased in the nucleus acumbens and CPF in animals treated with the CBD and amphetamine combination. The data presented here suggest TRPV1 receptors and the endocannabinoid anandamide seem to be involved with the antipsychotic profile of CBD. For the first time it has been shown that both pre-treatment with CBD or clozapine may alter the increase in overall DNA methylation induced by amphetamine. In addition, the expression of BDNF in the hippocampus and the expression of acetylated phospho-histone may be different mechanisms that deserve attention in relation to the antipsychotic profile of CBD.